68Ga-FAPI-04 PET-CT评估系统性硬化相关间质性肺病成纤维细胞活化与风险
这项单中心试点研究纳入21例系统性硬化相关间质性肺病(SSc-ILD)患者和21例无ILD对照,采用68Ga-FAPI-04 PET-CT检测肺内成纤维细胞活化。
要点
- 68Ga-FAPI-04 PET-CT可量化SSc-ILD肺内成纤维细胞活化,患者摄取显著高于无ILD对照。
- 基线FAPI摄取增高独立于HRCT范围和基线FVC预测ILD进展。
- 连续FAPI PET-CT变化与尼达尼布治疗反应一致,提示可用于风险分层。
核心结论
- 首次在人体中证明成纤维细胞活化与SSc-ILD肺纤维化活动及疾病进展相关。
- 68Ga-FAPI-04 PET-CT可能改善SSc-ILD的风险评估。
研究设计与样本
- 单中心试点研究,2018年9月10日至2020年4月8日连续纳入21例经HRCT确认的SSc-ILD患者和21例无ILD对照。
- 所有参与者基线接受68Ga-FAPI-04 PET-CT、HRCT和肺功能检查,SSc-ILD患者随访6个月复查HRCT和肺功能。
- 部分接受尼达尼布治疗的患者在6-10个月间复查68Ga-FAPI-04 PET-CT以评估变化。
主要发现
- 对照组因无高于本底的68Ga-FAPI-04摄取,全肺FAPI代谢活性体积(wlFAPI-MAV)和全肺总病灶FAPI(wlTL-FAPI)不可测。
- 广泛病变、既往ILD进展或高EUSTAR活动度患者的68Ga-FAPI-04摄取高于局限病变、既往稳定ILD或低EUSTAR活动度者。
临床怎么用
- 68Ga-FAPI-04 PET-CT有望作为评估SSc-ILD疾病活动和预测进展的分子影像工具。
- 基线FAPI摄取增高独立于HRCT范围和基线FVC预测ILD进展,可辅助风险分层。
- 连续FAPI PET-CT变化与尼达尼布治疗反应一致,可能用于监测治疗应答。
局限性
- 单中心试点研究,样本量小(21例SSc-ILD和21例对照),结论需更大规模研究验证。
- 随访时间较短(6个月),长期预后价值尚未确定。
- 连续PET-CT仅在部分尼达尼布治疗患者中获取,治疗反应评估存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) is the most common cause of death in systemic sclerosis. To date, the progression of systemic sclerosis-associated ILD is judged by the accrual of lung damage on CT and pulmonary function tests. However, diagnostic tools to assess disease activity are not available. Here, we tested the hypothesis that quantification of fibroblast activation by PET-CT using a 68Ga-labelled selective inhibitor of prolyl endopeptidase FAP (68Ga-FAPI-04) would correlate with ILD activity and disease progression in patients with systemic sclerosis-associated ILD. METHODS: Between Sept 10, 2018, and April 8, 2020, 21 patients with systemic sclerosis-associated ILD confirmed by high-resolution CT (HRCT) within 12 months of inclusion and with onset of systemic sclerosis-associated ILD within 5 years or signs of progressive ILD and 21 controls without ILD were consecutively enrolled. All participants underwent 68Ga-FAPI-04 PET-CT imaging and standard-of-care procedures, including HRCT and pulmonary function tests at baseline. Patients with systemic sclerosis-associated ILD were followed for 6 months with HRCT and pulmonary function tests. We compared baseline 68Ga-FAPI-04 PET-CT uptake with standard diagnostic tools and predictors of ILD progression. The association of 68Ga-FAPI-04 uptake with changes in forced vital capacity was analysed using mixed-effects models. Follow-up 68Ga-FAPI-04 PET-CT scans were obtained in a subset of patients treated with nintedanib (follow-up between 6-10 months) to assess change over time. FINDINGS: 68Ga-FAPI-04 accumulated in fibrotic areas of the lungs in patients with systemic sclerosis-associated ILD compared with controls, with a median standardised uptake value (SUV) mean over the whole lung of 0·80 (IQR 0·60-2·10) in the systemic sclerosis-ILD group and 0·50 (0·40-0·50) in the control group (p<0·0001) and a mean whole lung maximal SUV of 4·40 (range 3·05-5·20) in the systemic sclerosis-ILD group compared with 0·70 (0·65-0·70) in the control group (p<0·0001). Whole-lung FAPI metabolic active volume (wlFAPI-MAV) and whole-lung total lesion FAPI (wlTL-FAPI) were not measurable in control participants, because no 68Ga-FAPI-04 uptake above background level was observed. In the systemic sclerosis-ILD group the median wlFAPI-MAV was 254·00 cm3 (IQR 163·40-442·30), and the median wlTL-FAPI was 183·60 cm3 (98·04-960·70). 68Ga-FAPI-04 uptake was higher in patients with extensive disease, with previous ILD progression, or high EUSTAR activity scores than in those with with limited disease, previously stable ILD, or low EUSTAR activity scores. Increased 68Ga-FAPI-04 uptake at baseline was associated with progression of ILD independently of extent of involvement on HRCT scan and the forced vital capacity at baseline. In consecutive 68Ga-FAPI-04 PET-CTs, changes in 68Ga-FAPI-04 uptake was concordant with the observed response to the fibroblast-targeting antifibrotic drug nintedanib. INTERPRETATION: Our study presents the first in-human evidence that fibroblast activation correlates with fibrotic activity and disease progression in the lungs of patients with systemic sclerosis-associated ILD and that 68Ga-FAPI-04 PET-CT might improve risk assessment of systemic sclerosis-associated ILD. FUNDING: German Research Foundation, Erlangen Anschubs-und Nachwuchsfinanzierung, Interdisziplinäres Zentrum für Klinische Forschung Erlangen, Bundesministerium für Bildung und Forschung, Deutsche Stiftung Systemische Sklerose, Wilhelm-Sander-Foundation, Else-Kröner-Fresenius-Foundation, European Research Council, Ernst-Jung-Foundation, and Clinician Scientist Program Erlangen.
引用
- Bergmann C, Distler JHW, Treutlein C, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021. PMID: 38279381. doi:10.1016/S2665-9913(20)30421-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。